BioGaia Gestion

Gestion contrôle des critères 3/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Theresa Agnew

Directeur général

SEK 6.8m

Rémunération totale

Pourcentage du salaire du PDG	19.4%
Durée du mandat du directeur général	1.2yrs
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	3.5yrs
Durée moyenne du mandat des membres du conseil d'administration	3.5yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Theresa Agnew a-t-elle évolué par rapport aux bénéfices de BioGaia?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	SEK 337m
Jun 30 2024	n/a	n/a	SEK 402m
Mar 31 2024	n/a	n/a	SEK 371m
Dec 31 2023	SEK 7m	SEK 1m	SEK 365m

Rémunération vs marché: La rémunération totale de Theresa ($USD 613.68K ) est inférieure à la moyenne des entreprises de taille similaire sur le marché UK ($USD 1.45M ).

Rémunération et revenus: Données insuffisantes pour comparer la rémunération de Theresa avec les performances de l'entreprise.

PDG

Theresa Agnew (58 yo)

1.2yrs

Titularisation

SEK 6,750,250

Compensation

Ms. Theresa P. Agnew serves as President of BioGaia AB (publ) since September 2023 and serves as its Chief Executive Officer since 25 September 2023. She is a global business leader with consumer healthcar...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Peter Rothschild	Founder & Chairman	6.6yrs	SEK 1.33m	pas de données
Theresa Agnew	CEO & President	1.2yrs	SEK 6.75m	pas de données
Alexander Kotsinas	Executive VP & CFO	5yrs	SEK 3.07m	0.0030% SEK 317.9k
Ludvig Milesson	Chief Operating Officer	1.6yrs	pas de données	0.0012% SEK 132.7k
Gianfranco Grompone	Chief Scientific Officer and VP of Research & Development	4.8yrs	pas de données	pas de données
Caroline Mofors	Chief Legal Officer	1.8yrs	pas de données	pas de données
Linda Hagglund	Vice President of Marketing	3.5yrs	pas de données	0.0012% SEK 126.3k
Angelika Kjelldorff	Chief HR Officer	5.8yrs	pas de données	0.00049% SEK 52.4k
Sebastian Heimfors	VP & Chief Commercial Officer	2.7yrs	pas de données	pas de données
Jonathan Gromark	Sustainability Manager	no data	pas de données	pas de données
Keitaro Nomura	MD & President of BioGaia Japan Inc.	no data	pas de données	pas de données

3.5yrs

Durée moyenne de l'emploi

52yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 0GTN est considérée comme expérimentée (ancienneté moyenne 3.5 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Peter Rothschild	Founder & Chairman	6.6yrs	SEK 1.33m	pas de données
David E. Dangoor	Independent Deputy Board Chairman	21.8yrs	SEK 590.00k	1.73% SEK 185.1m
Vesa Koskinen	Director	1.5yrs	SEK 275.00k	pas de données
Barbro Friden	Director	1.5yrs	SEK 275.00k	0.00049% SEK 52.4k
Anthon Jahreskog	Independent Director	9.5yrs	SEK 405.00k	0.0040% SEK 427.0k
Vanessa Rothschild	Director	4.5yrs	SEK 275.00k	0.00016% SEK 17.1k
Benedicte Flambard	Director	2.5yrs	SEK 275.00k	pas de données
Outi Armstrong	Director	1.5yrs	SEK 275.00k	pas de données

3.5yrs

Durée moyenne de l'emploi

54yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 0GTN sont considérés comme expérimentés (ancienneté moyenne 3.5 ans).

BioGaia Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Vice President of Marketing recently sold kr407k worth of stock

Executive VP & CFO recently sold kr11m worth of stock

BioGaia AB (publ), Annual General Meeting, Apr 26, 2024

Biogaia AB (Publ) Appoints Theresa Agnew as CEO

BioGaia Appoints Theresa Agnew as New CEO, Effective September 25, 2023

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: kr0.36 (vs kr1.01 in 3Q 2023)

BioGaia AB (publ) to Report Q2, 2025 Results on Jul 18, 2025

Vice President of Marketing recently sold kr407k worth of stock

Executive VP & CFO recently sold kr11m worth of stock

Second quarter 2024 earnings released: EPS: kr1.10 (vs kr0.80 in 2Q 2023)

BioGaia AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025

First quarter 2024 earnings released: EPS: kr1.21 (vs kr1.15 in 1Q 2023)

Full year 2023 earnings released: EPS: kr3.62 (vs kr3.70 in FY 2022)

Full year 2023 earnings released: EPS: kr3.62 (vs kr3.70 in FY 2022)

Biogaia AB (Publ) Proposes an Extra Dividend

BioGaia AB (publ) to Report First Half, 2024 Results on Jul 07, 2024

Third quarter 2023 earnings released

BioGaia AB (publ), Annual General Meeting, Apr 26, 2024

Biogaia AB (Publ) Provides Preliminarily Earnings Guidance for Third Quarter 2023

Biogaia AB (Publ) Appoints Theresa Agnew as CEO

BioGaia AB (publ) Introduces BioGaia Prodentis KIDS in Sweden

BioGaia Appoints Theresa Agnew as New CEO, Effective September 25, 2023

Second quarter 2023 earnings released

BioGaia's probiotic Protectis increases SARS-CoV-2 antibody response in adults

Less than half of directors are independent

First quarter 2023 earnings released

BioGaia AB (Publ) Approves Dividend for 2022

Upcoming dividend of kr2.90 per share at 2.8% yield

Full year 2022 earnings released: EPS: kr3.70 (vs kr1.94 in FY 2021)

Independent Director recently bought kr51k worth of stock

Full year 2022 earnings released: EPS: kr3.70 (vs kr1.94 in FY 2021)

BioGaia AB (publ) Proposes Ordinary Dividend

Third quarter 2022 earnings released

Investor sentiment improved over the past week

BioGaia AB (publ) Provides Earnings Guidance for the Third Quarter of 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: kr0.78 (vs kr0.54 in 2Q 2021)

Biogaia AB (publ) Provides Earnings Guidance for the Second Quarter of 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

BioGaia AB (publ) Approves Extra Dividend

First quarter 2022 earnings released

Upcoming dividend of kr14.92 per share

BioGaia AB (publ) Provides Earnings Guidance for the First Quarter of 2022

BioGaia AB (publ) Proposes Dividend, Payable on 13 May 2022

Full year 2021 earnings released: EPS: kr9.72 (vs kr10.07 in FY 2020)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Biogaia AB (Publ) Proposes Ordinary Dividend

BioGaia's Probiotic Reduces Inflammation in Patients with Diverticulitis

BioGaia AB (publ) Announces First Patient Enrolled in Phase II Clinical Study Evaluating BGP345A for the Treatment of Opioid Induced Constipation (OIC-1)

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS kr2.71 (vs kr4.56 in 2Q 2020)

BioGaia AB (publ) (OM:BIOG B) acquired remaining 8% stake in MetaboGen AB for SEK 11.4 million.

Vice President of RA & Legal recently bought kr103k worth of stock

Vice President of RA & Legal recently bought kr103k worth of stock

Vice President of RA & Legal recently bought kr103k worth of stock

Biogaia AB (Publ) Approves Dividend

First quarter 2021 earnings released

Upcoming dividend of kr3.41 per share

Full year 2020 earnings released: EPS kr10.07

New 90-day low: kr419

CEO & President recently bought kr99k worth of stock

Full year 2020 earnings released: EPS kr10.07 (vs kr10.81 in FY 2019)

Revenue beats expectations

New 90-day low: kr444

BioGaia AB (publ) Elects Niklas Ringby as New Board Member

Market bids up stock over the past week

BioGaia AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.144 billion.